Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Nov 3, 2022 at 2:01 PM CET
Media Release
Copenhagen, Denmark, November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignancies
Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome
New data evaluating investigational medicines in Genmab's early portfolio of cancer immunotherapies will also be presented
Genmab to host 2022 R&D Update and ASH Data Review meeting December 12
Se hele programmet for Genmab/ASH:
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual
Nov 3, 2022 at 2:01 PM CET
Media Release
Copenhagen, Denmark, November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a variety of treatment settings and hematologic malignancies
Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome
New data evaluating investigational medicines in Genmab's early portfolio of cancer immunotherapies will also be presented
Genmab to host 2022 R&D Update and ASH Data Review meeting December 12
Se hele programmet for Genmab/ASH:
https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-64th-annual
11/12 2022 11:50 ProInvestorNEWS 3
108609 Janssen Presents First Data fromMajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
https://www.janssen.com/janssen-presents-first-data-majestec-2-trial-tecvayli-teclistamab-cqyv-combination-darzalex-faspro
https://www.janssen.com/janssen-presents-first-data-majestec-2-trial-tecvayli-teclistamab-cqyv-combination-darzalex-faspro
11/12 2022 11:51 ProInvestorNEWS 3108610 Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
https://www.janssen.com/janssen-presents-new-data-talquetamab-first-class-gprc5dxcd3-bispecific-antibody-suggesting-durable
https://www.janssen.com/janssen-presents-new-data-talquetamab-first-class-gprc5dxcd3-bispecific-antibody-suggesting-durable
11/12 2022 11:55 ProInvestorNEWS 3108611 ASH 2022: Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Re...
Recorded @ ASH 2022 PressBriefing, December 10/ More Info from ASH @ https://oncoletter.ch
Recorded @ ASH 2022 PressBriefing, December 10/ More Info from ASH @ https://oncoletter.ch
11/12 2022 14:09 ProInvestorNEWS 2108617 Monumen-TAL - I dismantle the ASH/ NEJM Talquetamab study ' First of the ASH 2022 video series
11/12 2022 21:03 ProInvestorNEWS 2108626 Talquetamab Generates High Response Rate in Hard-to-Treat Multiple Myeloma .
https://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=2392
https://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=2392
12/12 2022 06:21 ProInvestorNEWS 2108629 Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Ran
https://www.proinvestor.com/investornyt/914javascript:postreply(108608,108608);708/genmab-showcases-data-from-robust-development-program-evaluating-epcoritamab-duobody-cd3xcd20-in-patients-across-a-broad-ran
https://www.proinvestor.com/investornyt/914javascript:postreply(108608,108608);708/genmab-showcases-data-from-robust-development-program-evaluating-epcoritamab-duobody-cd3xcd20-in-patients-across-a-broad-ran
12/12 2022 07:15 ProInvestorNEWS 2108631 Genmab præsenterer lovende data for kræfthåb på konference i USA
https://www.proinvestor.com/investornyt/914741/genmab-praesenterer-lovende-data-for-kraefthab-pa-konference-i-usa
https://www.proinvestor.com/investornyt/914741/genmab-praesenterer-lovende-data-for-kraefthab-pa-konference-i-usa
12/12 2022 13:44 ProInvestorNEWS 2108649 Genmab har netop præsenteret stærke data på Annual Meeting and Exposition of the American Society of Hematology (ASH). Hør mere i denne video med Helge Larsen.
Disclaimer: Dette er ikke en anbefaling om køb eller salg af aktien. Helge Larsen har aktier i Genmab.
Disclaimer: Dette er ikke en anbefaling om køb eller salg af aktien. Helge Larsen har aktier i Genmab.
12/12 2022 14:34 ProInvestorNEWS 1108653 Genmab to Hold 2022 R&D Update and ASH Data Review Meeting https://www.proinvestor.com/investornyt
12/12 2022 17:12 ProInvestorNEWS 1108656 Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
https://www.prnewswire.com/news-releases/janssen-presents-efficacy-and-subgroup-analyses-from-maia-study-showing-long-term-results-of-darzalex-daratumumab-based-regimen-in-newly-diagnosed-transplant-ineligible-multiple-myeloma-301700443.html
https://www.prnewswire.com/news-releases/janssen-presents-efficacy-and-subgroup-analyses-from-maia-study-showing-long-term-results-of-darzalex-daratumumab-based-regimen-in-newly-diagnosed-transplant-ineligible-multiple-myeloma-301700443.html
13/12 2022 06:22 ProInvestorNEWS 1108675 2022 R&D Update and ASH Data Review Dec 12, 2022 at 8:00 PM EST Genmab hosted its 2022 R&D Update and ASH Data Review on Monday, December 12, 2022.
https://www.proinvestor.com/investornyt/915182/december-12-2022-800-pm-est-2022-rampd-update-and-ash-data-review
https://www.proinvestor.com/investornyt/915182/december-12-2022-800-pm-est-2022-rampd-update-and-ash-data-review
